NLS Pharmaceutics Announces the Completion of the Merger between NLS Pharma Ltd., NLS-1 Pharma Ltd. and NLS-0 Pharma, Unifying the Global Operations and Development of Nolazol

NLS Pharmaceutics Ltd (NLS), a Swiss biotech firm focusing on the development of novel treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and other cognitive disorders and impairments, today announced the closing of the merger of NLS Pharma Ltd., NLS-1 Pharma Ltd. and NLS-0 Pharma, effective immediately. The combined company was named "NLS Pharmaceutics Ltd." The sideways merger brings together the global operations and assets of the three companies in order to streamline the development of Nolazol^®, a controlled release formulation of mazindol that is currently being developed as a non-amphetamine DEA schedule C-4 treatment option for ADHD and narcolepsy, as well as a promising pipeline of early to late-stage compounds focusing on ADHD, sleep disorder and other rare diseases.

Leading the combined company as Chief Executive Officer is Alex Zwyer, who served as co-Founder and CEO of NLS Pharma Ltd. leading up to the merger.  Ronald Hafner will serve as Chairman of the board of directors.

"We are convinced that merging the operations, IP and other assets of these three businesses into a single company will significantly increase the attractiveness and visibility of NLS and its R&D projects," stated Mr. Zwyer. "We are excited to move forward as a single entity with a strong clinical program and rich product pipeline that we believe will continue to grow."

The Company’s recent Phase II study in ADHD for Nolazol^® demonstrated efficacy levels equivalent to, or greater than, those previously only seen with stimulant treatments, with a favorable treatment-related adverse event profile.  NLS Pharmaceutics is currently planning  Phase III clinical studies in ADHD for Nolazol^® in the U.S., which is expected to reach the U.S. market as soon as 2022/2023, pending regulatory approval and other factors.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.